Newly Identified Events in the RE-LY Trial
Stuart J. Connolly(Population Health Research Institute), Lars Wallentin(Uppsala University), Salim Yusuf(Population Health Research Institute), Michael D. Ezekowitz(Lankenau Institute for Medical Research), Paul Reilly(Boehringer Ingelheim (United States))
Cited by 681
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
|Stroke|2014|5.2k
Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study
|The Lancet|2005|2.9k
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
|New England Journal of Medicine|2017|2.4k